BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang X, Gu G, Li X, Zhang C. Lidocaine alleviates cisplatin resistance and inhibits migration of MGC-803/DDP cells through decreasing miR-10b. Cell Cycle 2020;19:2530-7. [PMID: 32892697 DOI: 10.1080/15384101.2020.1809914] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Tabnak P, Masrouri S, Geraylow KR, Zarei M, Esmailpoor ZH. Targeting miRNAs with anesthetics in cancer: Current understanding and future perspectives. Biomed Pharmacother 2021;144:112309. [PMID: 34653761 DOI: 10.1016/j.biopha.2021.112309] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Loren P, Saavedra N, Saavedra K, De Godoy Torso N, Visacri MB, Moriel P, Salazar LA. Contribution of MicroRNAs in Chemoresistance to Cisplatin in the Top Five Deadliest Cancer: An Updated Review. Front Pharmacol 2022;13:831099. [PMID: 35444536 DOI: 10.3389/fphar.2022.831099] [Reference Citation Analysis]
3 Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Hushmandi K, Rahmanian V, Entezari M, Girish YR, Sharath Kumar KS, Aref AR, Makvandi P, Ashrafizadeh M, Zarrabi A, Khan H. Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: Approaching to a new era of cancer chemotherapy. Life Sci 2021;277:119430. [PMID: 33789144 DOI: 10.1016/j.lfs.2021.119430] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
4 Mirzaei S, Hushmandi K, Zabolian A, Saleki H, Torabi SMR, Ranjbar A, SeyedSaleh S, Sharifzadeh SO, Khan H, Ashrafizadeh M, Zarrabi A, Ahn KS. Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies. Molecules 2021;26:2382. [PMID: 33921908 DOI: 10.3390/molecules26082382] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
5 Liu F, Shi Y, Liu Z, Li Z, Xu W. The emerging role of miR-10 family in gastric cancer. Cell Cycle 2021;20:1468-76. [PMID: 34229543 DOI: 10.1080/15384101.2021.1949840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wall TP, Buggy DJ. Perioperative Intravenous Lidocaine and Metastatic Cancer Recurrence - A Narrative Review. Front Oncol 2021;11:688896. [PMID: 34408981 DOI: 10.3389/fonc.2021.688896] [Reference Citation Analysis]
7 Zhang C, Xie C, Lu Y. Local Anesthetic Lidocaine and Cancer: Insight Into Tumor Progression and Recurrence. Front Oncol 2021;11:669746. [PMID: 34249706 DOI: 10.3389/fonc.2021.669746] [Reference Citation Analysis]
8 Liu T, Jiang F, Yu LY, Wu YY. Lidocaine represses proliferation and cisplatin resistance in cutaneous squamous cell carcinoma via miR-30c/SIRT1 regulation. Bioengineered 2022;13:6359-70. [PMID: 35212616 DOI: 10.1080/21655979.2022.2031419] [Reference Citation Analysis]